Entera Bio (ENTX) makes oral peptide therapies, validating its disruptive N-Tab oral peptide proprietary technology platform. Its leading pipeline candidate is EB613, an oral, osteoanabolic (bone building) once-daily tablet for treating osteoporosis, a bone disease that develops when bone mass decreases, leading to an increase in the risk of fractures. A phase IIb study of the EB613 tablets met the primary and secondary endpoints. Entera Bio plans to begin a phase III registrational study on EB613 once the ...